Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITAR
2022-501130-33-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in immune checkpoint inhibitor-associated arthritis (ICI-IA) comparing Tocilizumab plus prednisolone with Prednisolone alone (2 arms). Primary endpoint: CDAI low disease activity at week 16. Planned start Oct 2023; status: authorised.
02
Drugs
tocilizumabprednisolone
03
Conditions
immune checkpoint inhibitor-associated arthritis (ICI-IA)
Beyond the preview
Go deeper on 2022-501130-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501130-33-00.